# Danaher stock near historic low as $9.9 bn Masimo deal fuels growth

**Published:** 2026-07-17T02:32:56.765Z  
**Topic:** S P 500  
**Sentiment:** neutral  
**Publisher:** TrendWatcher — https://www.trendwatcher.in/article/7fecff9d-43ad-4235-8f9f-12df30a85f07

Danaher shares trade near the low end of historical multiples after a $9.9 bn Masimo acquisition and a $125 m cost‑savings target, signaling a potential

Danaher (DHR) shares are hovering at the low end of their long‑term valuation range, with analysts pointing to a $9.9 billion Masimo acquisition and a $125 million cost‑savings target as catalysts for earnings acceleration【3】.

| At a glance | |
|---|---|
| Acquisition size | $9.9 bn (Masimo) |
| Cost‑savings target | $125 m |
| EPS accretion estimate | 15‑20 c per share |
| Valuation | Near low end of historical multiples |

## Acquisition and cost‑savings drive

Danaher’s recent purchase of pulse‑oximetry leader Masimo for $9.9 billion expands its high‑margin medical‑device portfolio. The deal is expected to be “roughly 15 to 20 cents accretive to adjusted earnings per share in the first full year post‑close,” according to CFO Matthew Gugino during the April earnings call【3】. Management also aims to generate $125 million in cost reductions by applying the Danaher Business System (DBS) to Masimo’s operations, a figure described as “almost certainly conservative” given the scale of the target company’s inefficiencies【3】.

## Earnings outlook and market positioning

Danaher’s core life‑sciences segment is emerging from a two‑year post‑pandemic destocking slump, which should lift recurring revenue and improve margins. Combined with the anticipated Masimo margin improvements, analysts see a re‑acceleration of earnings growth. Despite these fundamentals, the stock remains priced at the lower end of its historical multiple range, suggesting the market is still valuing the company on a “depressed, cyclical‑trough earnings” basis【3】. This valuation gap positions Danaher as a “world‑class asset currently on sale,” according to the CNBC commentary.

## What to watch
- Danaher’s Q3 earnings release for actual cost‑savings realized and any update to the EPS accretion guidance.  
- Progress on integrating Masimo’s product lines and the impact on high‑margin recurring revenue.  
- Macro data on bioprocessing demand, which could further lift the life‑sciences segment.

The juxtaposition of a low valuation with tangible acquisition synergies and cost‑cutting targets makes Danaher a focal point for investors seeking exposure to a “master contractor” model in healthcare, while the upcoming earnings report will test whether the anticipated upside materializes.

## Sources
1. The Motley Fool — [Prediction: This Will Be Nvidia's Stock Price Next... | The Motley Fool](https://www.fool.com/investing/2026/07/14/prediction-this-will-be-nvidias-stock-price-next-y/)
2. Medium — [Great Location But House Needs Work Before We Can Call... | Medium](https://medium.com/@brokerleonardfields/great-location-but-house-needs-work-before-we-can-call-it-home-bf87ed65f791)
3. CNBC — [Buy the contractor before the renovation is complete: This stock's next growth phase is taking shape](https://www.cnbc.com/2026/07/16/buy-the-contractor-before-the-renovation-is-complete-this-stocks-next-growth-phase-is-taking-shape.html)

---
Cite as: TrendWatcher, "Danaher stock near historic low as $9.9 bn Masimo deal fuels growth", https://www.trendwatcher.in/article/7fecff9d-43ad-4235-8f9f-12df30a85f07